Irbesartan
- Atc Codes:C09CA04
- CAS Codes:138402-11-6
- PHARMGKB ID:138402-11-6
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Aprovel, Fensoberax, Ifirmasta, Irbesartan, Irbetyrol, Karvea; Belgium: Aprovel; Bulgaria: Aprovel, Irbesartan, Karvea; Cyprus: Karvea; Czech Republic: Aprovel, Ifirmasta, Irbesartan, Karvea; Denmark: Aprovel, Karvea; Estonia: Aprovel, Irbesartan, Iprestan, Karvea; France: Aprovel; Germany: Aprovel, Ifirmasta, Irbesartan, Karvea, Mefam; Greece: Aprovel, Irbesartan, Karvea; Hungary: Aprovel, Irbec, Irbesartan, Irprestan, Irtucalan, Karvea; Ireland: Aprovel, Ifirmasta, Irbesan, Irbesartan, Irprestan, Karvea; Italy: Aprovel, Karvea; Latvia: Aprovel, Ifirmasta, Irbesartan, Karvea; Lithuania: Aprovel, Ifirmasta, Irbesartan, Karvea; Luxembourg: Aprovel, Irbesartan, Karvea; Malta: Aprovel, Ifirmasta, Irbesartan, Karvea; Netherlands: Aprovel, Artivesan, Irberan, Irbesartan, Irtec, Karvea; Poland: Aprovel, Ifirmasta, Irbesartan, Karvea; Portugal: Abavil, Aprovel, Ifirmasta, Irbesartan, Karvea; Romania: Aprovel, Irbec, Irbegamma, Irbesartan, Irkartaban, Karvea; Slovakia: Aprovel, Ifirmasta, Irbesartan, Irtucalan, Karvea; Slovenia: Aprovel, Iraben, Irbesartan, Karvea; Spain: Aprovel, Irbesartan, Karvea; Sweden: Aprovel, Ifirmasta, Irbesartan, Karvea; UK: Aprovel.
North America
Canada: Avapro; USA: Avapro.
Latin America
Argentina: Adana, Aprovel, Avapro; Brazil: Aprovel, Ávapro; Mexico: Aprovel, Avapro.
Asia
Japan: Avapro, Irbetan.
Drug combinations
Irbesartan and Hydrochlorothiazide
Chemistry
Irbesartan: C~25~H~28~N~6~O. Mw: 428.53. (1) 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-; (2) 2-Butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one. CAS-138402-11-6 (1996).
Pharmacologic Category
Angiotensin II Receptor Antagonists. (ATC-Code: C09CA04).
Mechanism of action
Irbesartan binds to AT1 angiotensin II receptor. This binding prevents angiotensin II from binding to receptor, thereby blocking the vasoconstriction and aldosterone-secreting effects of angiotensin II.
Therapeutic use
Treatment of hypertension alone or in combination with other antihypertensives. Treatment of diabetic nephropathy in type 2 diabetes mellitus (non-insulin-dependent, NIDDM) and hypertension.
Pregnancy and lactiation implications
Possible fetal harm and/or death if used in 2^nd^ and 3^rd^ trimesters of pregnancy. Angiotensin II receptor antagonists should be avoided in the first three months of pregnancy. Contraindicated during lactation.
Unlabeled use
To slow rate of progression of aortic-root dilation in pediatric patients with Marfan’s syndrome.
Contraindications
Hypersensitivity to irbesartan or any component of the formulation.
Warnings and precautions
Hyperkalemia might occur. Renal function deterioration and/or increases in serum creatinine. Use with caution in significant aortic/mitral stenosis, in unstented unilateral/bilateral renal artery stenosis, or with pre-existing renal insufficiency, and severe renal impairment. May cause injury and death to developing fetus when used in 2^nd^ and 3^rd^ trimesters of pregnancy. Possible symptomatic hypotension, particularly in volume- and/or salt-depleted patients. Anaphylactoid reactions and/or angioedema possible. Possible oliguria, progressive azotemia, and, rarely, acute renal failure and/or death in severe CHF. Blood pressure reduction may be smaller in black patients.